SCHEMBL2298316

SCHEMBL2298316

O=S(=O)(O)c1ccc(O)c(I)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
HSD17B10 Q99714 4/20 0.59
KDM4E B2RXH2 1/20 0.53
HPGD P15428 1/20 0.53
LMNA P02545 1/20 0.48
SERPINE1 P05121 3/20 0.45
NT5E P21589 3/20 0.44
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA9 Q16790 2/20 0.44
CA7 P43166 2/20 0.44
CA14 Q9ULX7 2/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
TSHR P16473 3/20 0.41
PTPN1 P18031 2/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503638 0.98 ALDH1A1 (0.57) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL29382034 0.81 ALDH1A1 (0.68) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL307133 0.81 ALDH1A1 (0.68) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL1368815 0.81 ENPP2 (0.50) ALDH1A1HSD17B10LMNASERPINE1CA12
SCHEMBL6391731 0.81 PTPN1 (0.52) ALDH1A1HSD17B10LMNASERPINE1CA12
SCHEMBL5097099 0.79 ALDH1A1 (0.65) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL6368593 0.79 ALDH1A1 (0.65) ALDH1A1HSD17B10KDM4EHPGDLMNA
Ammonia Solution, Strong SCHEMBL2450277 0.79 ALDH1A1 (0.65) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL9492667 0.79 ALDH1A1 (0.65) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL8516709 0.77 ALDH1A1 (0.63) ALDH1A1HSD17B10KDM4EHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1083937-B1 RADIOIOINATED PHENOLS FOR BRACHYTHERAPY DOW GLOBAL TECHNOLOGIES INC (US) 2004-02-11 EP claimed
US-9181280-B2 Factor VIIa inhibitor PHARMACYCLICS LLC (US) 2015-11-10 US disclosed
US-20140221667-A1 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2014-08-07 US disclosed
US-8729117-B2 Factor VIIa inhibitor PHARMACYCLICS, INC. (US) 2014-05-20 US disclosed
US-20140080879-A1 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2014-03-20 US disclosed
US-8415328-B2 Factor VIIa inhibitor PHARMACYCLICS, INC (US) 2013-04-09 US disclosed
US-20110207939-A1 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2011-08-25 US disclosed
US-20080275250-A1 Factor Viia Inhibitor PHARMACYCLICS, INC. (US) 2008-11-06 US disclosed
US-20080242644-A1 Factor Viia Inhibitor PHARMACYCLICS, INC. (US) 2008-10-02 US disclosed
CN-1976903-A Factor VIIa inhibitor PHARMACYCLICS INC (US) 2007-06-06 CN disclosed
WO-2005121102-A2 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2005-12-22 WO disclosed
WO-2005118554-A2 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2005-12-15 WO disclosed
US-6861044-B2 Radioiodinated sulfonated phenols and process therefore THE DOW CHEMICAL COMPANY (US) 2005-03-01 US disclosed
EP-1083937-B1 RADIOIOINATED PHENOLS FOR BRACHYTHERAPY DOW GLOBAL TECHNOLOGIES INC (US) 2004-02-11 EP disclosed
US-6506364-B1 Administering such as sodium 3-iodo-4-hydroxybenzene sulfonate which is rapidly excreted without significant tissue uptake THE DOW CHEMICAL COMPANY 2003-01-14 US disclosed
US-6506363-B1 Iodination; purification via reduction to iodide salt with such as sodium metabisulfite or thiosulfate and precipitation with silver nitrate followed by ion exchange removal of excess silver ions THE DOW CHEMICAL COMPANY 2003-01-14 US disclosed
US-20020081662-A1 Radioiodinated sulfonated phenols and process therefore SIMON JAIME (US) 2002-06-27 US disclosed
US-6315979-B1 Radioiodinated sulfonated phenols for brachytherapy THE DOW CHEMICAL COMPANY 2001-11-13 US disclosed
EP-1083937-A1 RADIOIOINATED PHENOLS FOR BRACHYTHERAPY THE DOW CHEMICAL COMPANY (US) 2001-03-21 EP disclosed
WO-1999062564-A1 RADIOIODINATED PHENOLS FOR BRACHYTHERAPY THE DOW CHEMICAL COMPANY (US) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242644-A1 Factor Viia Inhibitor F7, F9, F5 ALDH1A1 3359/4885HSD17B10 3295/4885KDM4E 1344/4885
US-20110207939-A1 FACTOR VIIA INHIBITOR F7, F9, F5 ALDH1A1 3359/4885HSD17B10 3295/4885KDM4E 1344/4885
US-20140080879-A1 FACTOR VIIA INHIBITOR F7, F9, F5 ALDH1A1 3359/4885HSD17B10 3295/4885KDM4E 1344/4885
US-20140221667-A1 FACTOR VIIA INHIBITOR F7, F9, F5 ALDH1A1 3359/4885HSD17B10 3295/4885KDM4E 1344/4885
US-20080275250-A1 Factor Viia Inhibitor F7, F9, F5 ALDH1A1 3376/4885HSD17B10 3298/4885KDM4E 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.